The estimated Net Worth of Victor Vaughn is at least $534 Тысяча dollars as of 18 April 2018. Victor Vaughn owns over 17,850 units of Supernus Pharmaceuticals Inc stock worth over $534,390 and over the last 12 years Victor sold SUPN stock worth over $0.
Victor has made over 6 trades of the Supernus Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Victor exercised 17,850 units of SUPN stock worth $374,672 on 18 April 2018.
The largest trade Victor's ever made was exercising 60,000 units of Supernus Pharmaceuticals Inc stock on 5 April 2018 worth over $621,600. On average, Victor trades about 13,681 units every 8 days since 2013. As of 18 April 2018 Victor still owns at least 17,194 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Victor Vaughn stock trades at the bottom of the page.
Victor's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE, MD, 20850.
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell и Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: